Business Context and Reporting Period
Compugen Ltd., a genomics-based drug and diagnostic discovery company, reported its fourth quarter and full-year financial results for the period ended December 31, 2003. The filing, submitted on February 4, 2004, details the company's transition from a service-based model to a focus on its proprietary therapeutic protein pipeline and discovery engines.
Key Financial Metrics
| Metric | Q4 2003 | Q4 2002 | Full Year 2003 | Full Year 2002 |
|---|---|---|---|---|
| Total Revenues | $1.4 million | $2.7 million | $8.8 million | $11.1 million |
| Net Loss | $3.5 million | $3.2 million | $11.4 million | $12.2 million |
| Loss Per Share | $0.13 | $0.12 | $0.43 | $0.47 |
| Cash and Equivalents (Year End) | $60.5 million (Dec 31, 2003) | |||
| Operating Expenses (Full Year) | $23.0 million (2003) vs $26.1 million (2002) |
Liquidity and Debt: As of December 31, 2003, the company held $60.5 million in cash, cash equivalents, and marketable securities. Total current liabilities were $5.2 million. The filing does not disclose specific long-term debt obligations, though accrued severance pay of $2.0 million is listed under long-term liabilities.
Material Changes Versus Prior Period
- Revenue Decline: Full-year revenues decreased 21% to $8.8 million from $11.1 million in 2002. Q4 revenues dropped 49% to $1.4 million from $2.7 million. This decline is attributed to the divestiture of certain product lines as the company shifts focus to its discovery-based activities.
- Loss Reduction: Despite lower revenues, the net loss for the full year improved to $11.4 million from $12.2 million in 2002, driven by a reduction in total operating expenses.
- Cash Position: Cash balances decreased by $6.8 million year-over-year, a reduction described by management as "substantially less than expected" due to timing of receipts and lower-than-budgeted expenditures.
Guidance, Outlook, and Risks
2004 Financial Guidance:
- Cash Burn: Anticipated to be in the range of $15 million to $17 million for calendar year 2004.
- Cash Balance: Expected year-end 2004 cash balance is approximately $45 million.
- Revenues: Budgeted at approximately $5 million for 2004, significantly lower than 2003 actuals, reflecting the strategic shift away from legacy product marketing.
- R&D Expenses: Expected to remain the largest expenditure category, accounting for over 50% of total operating expenses.
Management Commentary: CEO Mor Amitai highlighted progress in the therapeutic protein pipeline, the development of discovery engines, and strengthened intellectual property. The company plans to add six new proteins to its pipeline in 2004 and aims to have a minimum of two therapeutic proteins enter human clinical trials annually in the mid-term.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks identified include changes in collaborator relationships, competitive pressures, technological development risks, and the ability to retain customers. The company is also seeking partners and additional financial resources to advance its Universal Lead Discovery Program.
Investor Verification Checklist
- Verify the sustainability of the projected $15-17 million cash burn rate against actual quarterly spending.
- Confirm the status of the $5 million revenue budget for 2004 given the divestiture of legacy product lines.
- Monitor progress on the "Universal Lead Discovery Program" and the timeline for securing partners or additional funding.
- Track the advancement of the therapeutic protein pipeline toward the goal of entering human clinical trials.
- Review the composition of the $60.5 million cash balance to ensure liquidity for the projected 2004 burn rate.